Skip to main content
Sign In
 

RNA Clinical Discovery


RNA Clinical Discovery

The goal of the Clinical Discovery group is to develop new RNA technologies for disease diagnosis and treatment.

In recent years several successful RNA therapies have been introduced to the market. An exceptional feature of RNA therapeutics is their ability to target any RNA vis complementary sequence, enabling therapies for many diseases. We believe RNA therapies will become increasingly common mainstream clinical tools in the relatively short-term future.

RNAs are often very informative readouts of disease status: the presence or absence of particular RNAs and isoforms can be specific to particular pathologic conditions (e.g., infection, cancer, and ischemia) and therefore have value. However, because the transcriptomes of normal and diseased cell types are complex and often poorly characterized, the potential utility of RNAs as biomarkers has not been fully exploited.

The Denver/Boulder area is a major hub of RNA biotechnology and we will form new partnerships with companies. For example, miRagen is a clinical stage biopharmaceutical company that develops RNA-targeting therapies with a specific focus on microRNAs and diseases of high unmet medical need. 

A goal of the RNA Bioscience Initiative is to provide a fluid pipeline from basic research to development of RNA-based therapeutics and diagnostics at the Anschutz Medical Campus.

Additional faculty will be recruited to enhance this research area.

Dr. Craig Jordan heads the RNA Clinical Discovery group. ​   

Affiliated Faculty

Tom Anchordoquy, PhD - Development of synthetic delivery systems for use in nucleic acids-based therapies 

Craig Jordan, PhD - Characterization and targeting of leukemia stem cells

Berenice Gitomer PhD - miRNAs as biomarkers for kidney disease

Eric Poeschla, MDViral replication, host innate immunity to viruses, and viral disease pathogenesis

Dmitri Simberg, PhD - Engineered nanoparticles in the human body